Document Detail

Nebivolol: a third-generation beta-adrenergic blocker.
MedLine Citation:
PMID:  16822893     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To describe the pharmacologic and pharmacokinetic properties of a new beta-adrenergic blocker, nebivolol, and review the literature evaluating its efficacy in the treatment of hypertension and heart failure. DATA SOURCES: Articles were identified through searches of MEDLINE (1996-May 2006) and International Pharmaceutical Abstracts (1970-May 2006), using the key word nebivolol. Additional references were selected from the bibliographies of the articles cited. Searches were not limited by language, time, or human subject. STUDY SELECTION AND DATA EXTRACTION: Preclinical studies evaluating the pharmacologic and pharmacokinetic properties of nebivolol in humans were selected for review. Randomized, controlled, blinded clinical trials assessing the efficacy of nebivolol for the treatment of hypertension and heart failure were also included. DATA SYNTHESIS: Preclinical data have established nebivolol as a third-generation beta-adrenergic blocker, as it possesses vasodilatory properties that contribute to its hemodynamic effects beyond those achieved at beta-adrenergic receptors. Short-term, randomized, controlled clinical trials have shown nebivolol to be as effective as other antihypertensive therapies at lowering blood pressure. One long-term trial showed a significant reduction in death and hospital admissions for cardiovascular causes when nebivolol was compared with placebo in patients with heart failure (31.1% vs 65.3%; HR 0.86; 95% CI 0.74 to 0.99). CONCLUSIONS: Nebivolol is a novel beta-adrenergic blocker that possesses unique pharmacologic properties, compared with other agents in its class. Nebivolol appears to be as effective as other antihypertensive agents at lowering blood pressure and possesses benefits for patients with heart failure. Additional studies are needed to address the long-term benefits of nebivolol for hypertension, to compare nebivolol with other beta-adrenergic blockers for heart failure, and to investigate the clinical relevance of nitric oxide-mediated vasodilation.
Angie Veverka; Donald S Nuzum; Jamie L Jolly
Related Documents :
7838803 - Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, i...
6160323 - Effects of chronic beta-adrenoceptor antagonism on plasma catecholamines and blood pres...
23073243 - Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and tg...
Publication Detail:
Type:  Journal Article; Review     Date:  2006-07-05
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  40     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:    2006 Jul-Aug
Date Detail:
Created Date:  2006-08-02     Completed Date:  2007-02-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1353-60     Citation Subset:  IM    
School of Pharmacy, Wingate University, NC 28174, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / adverse effects,  pharmacokinetics,  pharmacology*
Benzopyrans / adverse effects,  pharmacokinetics,  pharmacology*
Drug Interactions
Ethanolamines / adverse effects,  pharmacokinetics,  pharmacology*
Heart Failure / drug therapy
Hypertension / drug therapy
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Benzopyrans; 0/Ethanolamines; 99200-09-6/nebivolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Perioperative management of the obese orthopaedic patient.
Next Document:  Intractable epistaxis associated with topiramate administration.